Analysis of CA 125, CA 19-9, CA 15-3, CEA and AFP in chronic heart failure

9-SUMMARYAnalysis of CA 125, CA 19-9, CA 15-3, CEA, AFP levels in patients withchronic heart failureBackground and aims: It has been suggested that serum levels of tumour markers areelevated in patients with chronic heart failure (HF). The purposes of this study were todetermine serum levels of CA 125 and other tumour markers (CA 19-9, CA 15-3, CEA, andAFP) in HF patients, and to compare HF patients and healthy control subjects. Moreover, weinvestigated the relationship between the tumour markers and their functional capacities inthese patients.Materials and methods: Serum levels of CA 125 and other tumour markers (CA 19-9, CA15-3, CEA, and AFP) were determined in 30 heart failure patients (21 males and 9 females;age 62.2±9.2 years). Serum levels of these tumour markers were also evaluated in 30 healthyvolunteers (22 males and 8 females; age 58.6±13.1 years). Serum levels of the tumourmarkers (CA 125, CA 19-9, CA 15-3, CEA and AFP) were determined by chemiluminescentenzyme immunoassay methods (DPC, Los Angeles, USA). According to the New York HeartAssociation (NYHA) HF patients were divided into two groups: mild HF groups I (n=7) andsevere HF groups II (n=23).Results: Serum levels of CA 125 were significantly higher in HF patients than in normalcontrols (41.4±5 U/ml vs. 9.7±4.7 U/ml; p<0.0001 for all). However, there were nosignificant differences in serum levels of other tumour markers when compared to thecontrols (p>0.05 for all). Serum levels of CA 125 in the group II patients were significantlyhigher than in the group I patients (51.2 ± 15.3 U/ml vs. 9.3 ± 1.8 U/ml; p=0.006,respectively).37Conclusion: We have shown that only CA 125 seems to be closely related to the presenceand severity of HF. CA 19-9, CA 15-3, CEA and AFP weren?t related to the presence andseverity of HF.Keywords: Tumour markers, CA 125, Heart failure38